3- (1- (4- phenoxyphenyl)- 3- (2- phenylethyl)- 1H- indol- 5- yl)propanoic acid

inhibits cytosolic phospholipase A2alpha; structure in first source

Also Known As:

ASB14780

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - 3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid: 1
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - 3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid: 1
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - 3-(1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl)propanoic acid: 1

Experts

1.	Akiba, Satoshi: 1 article (03/2016)
2.	Hayashi, Yasuhiro: 1 article (03/2016)
3.	Ishihara, Keiichi: 1 article (03/2016)
4.	Kanai, Shiho: 1 article (03/2016)
5.	Kawashita, Eri: 1 article (03/2016)
6.	Nagahira, Kazuhiro: 1 article (03/2016)
7.	Tomoo, Toshiyuki: 1 article (03/2016)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 03/01/2016 - "ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease." 03/01/2016 - "The present findings suggest that an IVA-PLA2 inhibitor, such as ASB14780, could be useful for the treatment of nonalcoholic fatty liver diseases, including fatty liver and hepatic fibrosis. "
2.	Fibrosis (Cirrhosis) 03/01/2016 - "Importantly, ASB14780 also reduced the development of fibrosis even in matured hepatic fibrosis. " 03/01/2016 - "The daily coadministration of ASB14780 markedly ameliorated liver injury and hepatic fibrosis following 6 weeks of treatment with CCl4. " 03/01/2016 - "The present findings suggest that an IVA-PLA2 inhibitor, such as ASB14780, could be useful for the treatment of nonalcoholic fatty liver diseases, including fatty liver and hepatic fibrosis. " 03/01/2016 - "We herein demonstrate the beneficial effects of ASB14780 (3-[1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl]propanoic acid 2-amino-2-(hydroxymethyl)propane-1,3-diol salt), an orally active IVA-PLA2 inhibitor, on the development of fatty liver and hepatic fibrosis in mice. "
3.	Fatty Liver 03/01/2016 - "Additionally, ASB14780 also reduced HFCD-induced lipid deposition not only in the liver, but also in already established fatty liver. " 03/01/2016 - "The present findings suggest that an IVA-PLA2 inhibitor, such as ASB14780, could be useful for the treatment of nonalcoholic fatty liver diseases, including fatty liver and hepatic fibrosis. " 03/01/2016 - "We herein demonstrate the beneficial effects of ASB14780 (3-[1-(4-phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl]propanoic acid 2-amino-2-(hydroxymethyl)propane-1,3-diol salt), an orally active IVA-PLA2 inhibitor, on the development of fatty liver and hepatic fibrosis in mice. "

Related Drugs and Biologics

1.	Group IV Phospholipases A2
2.	Salts
3.	Propionates
4.	Propane
5.	Lipids